Cancer Stem Cell News 6.36 September 13, 2017 | |
![]() | |
| |
TOP STORYKDM4 Inhibition Targets Breast Cancer Stem-Like Cells The authors describe an orally available, selective and potent KDM4 inhibitor with unique preclinical characteristics. To assess the anti-tumor properties of QC6352, they established a method to isolate and propagate breast cancer stem-like cells from individual triple-negative tumors resected from patients after neoadjuvant chemotherapy. [Cancer Res] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Significance of Perivascular Tumor Cells Defined by CD109 Expression in Progression of Glioma The authors identified CD109, a glycosylphosphatidylinositol- anchored protein and regulator of multiple signalling pathways, as a critical regulator of the progression of lower-grade glioma by clinicopathological and whole genome sequencing analysis of tissues from human glioma. The importance of CD109-positive perivascular tumor cells was confirmed not only in human lower-grade glioma tissues, but also in a mouse model that recapitulated human glioma. [J Pathol] Abstract Genetic Evolution of Glioblastoma Stem-Like Cells from Primary to Recurrent Tumor Glioblastoma (GBM) contains a cell hierarchy driven by stem-like cells (GSCs), responsible for tumor generation, therapeutic resistance and relapse. Researchers analyzed the mutational profile of GSCs isolated from either human primary GBMs (primary GSCs) or their matched tumors recurring after surgery and chemo-radiotherapy (recurrent GSCs). They found that recurrent GSCs can accumulate temozolomide-related mutations over primary GSCs, following both linear and branched patterns. [Stem Cells] Abstract LGR5 Promotes Cancer Stem Cell Traits and Chemoresistance in Cervical Cancer The authors modulated the expression of LGR5 using an overexpression vector or short hairpin RNA in cervical cancer cell lines. They demonstrated that elevated LGR5 expression in cervical cancer cells increased tumorsphere-forming efficiency; conferred chemoresistance to cisplatin treatment; augmented cell migration, invasion and clonogenicity; and elevated the levels of stem cell-related transcription factors in vitro. [Cell Death Dis] Full Article Researchers examined ICG-001 and its potential role as a therapeutic in gastric cancer. The gastric cancer cell lines SGC-7901, MGC-803, BGC-823 and MKN-45 were used in vitro and in vivo. The abilities of cell proliferation, tumor sphere formation, metastasis, tumorgenesis and chemoresistance to chemotherapy drugs in vitro were evaluated by MTT assay, colony formation assay, flow cytometry, migration and invasion assay, and tumor spheres culture. [J Exp Clin Cancer Res] Abstract Scientists examined the molecular mechanisms by which SATB2 induced malignant transformation of colorectal epithelial cells. SATB2 induced malignant transformation and these transformed cells gained the characteristics of CSCs by expressing stem cell markers and transcription factors. [Sci Rep] Full Article Investigators examined the influence of sorafenib, a multiple-receptor tyrosine kinase inhibitor used as a first-line treatment for advanced hepatocellular carcinoma, on EpCAM+ and CD90+ cancer stem cells. CD90+ cells showed higher c-Kit gene/protein expression than EpCAM+ cells. [Sci Rep] Full Article Researchers investigated the antitumor effect of GD55 on prostate CSC-like cells in vitro and in vivo. Prostate CSC-like sphere cells were acquired and enriched by culturing DU145, LNCap or P3 prostate cancer cells in suspension. [Acta Pharmacol Sin] Abstract The authors aimed to investigate whether interleukin-6 (IL-6) knockdown may enhance the efficacy of cisplatin in laryngeal cancer stem cells and the potential involvement of the signal transducer and activator of transcription 3 and hypoxia-inducible factor 1 (HIF1) in this effect. [Cancer Cell Int] Full Article | |
| |
REVIEWSIntranasal Delivery of Stem Cell-based Therapies for the Treatment of Brain Malignancies The authors describe nasal anatomy, routes of stem cell migration, and factors affecting stem cell delivery to hard-to-reach tumors. They discuss the molecular mechanisms underlying stem cell migration following delivery, as well as possible stem cell effector functions to be considered in combination with intranasal delivery. [Expert Opin Drug Deliv] Abstract Visit our reviews page to see a complete list of reviews in the cancer stem cell research field. | |
| |
INDUSTRY NEWSSandoz Proposed Biosimilar Rituximab Accepted for Review by the FDA Sandoz announced that the FDA has accepted its Biologics License Application under the 351 (k) pathway for a proposed biosimilar to the reference medicine, Rituxan®†. [Sandoz] Press Release DelMar Pharmaceuticals announced the initiation of a Phase II clinical trial for its lead agent VAL-083 in newly diagnosed MGMT-unmethylated glioblastoma multiforme (GBM). The biomarker-driven clinical trial will explore safety and efficacy of chemoradiation with VAL-083 as an alternative to standard-of-care temozolomide in patients with MGMT-unmethylated GBM. [DelMar Pharmaceuticals] Press Release | |
| |
POLICY NEWSUK Gender-Equality Scheme Spreads Across the World A program that grades UK universities on gender equality in science is going global. Versions of the rating scheme have started up in the past two years in Australia and Ireland, and a small-scale pilot begins next month in the United States. [Nature News] Editorial South Korean Researchers Lobby Government to Lift Human-Embryo Restrictions More than a decade after a fraud scandal in stem cell science rocked South Korea, scientists in the field are ramping up pressure on the government to relax the country’s strict regulations on human-embryo research — which many researchers label a ban. The nation’s bioethics committee held a public forum with the Ministry of Health and Welfare in Seoul, inviting 11 researchers and scholars to discuss possible changes to the country’s bioethics policies on research. [Nature News] Editorial Congress Rejects Trump Proposals to Cut Health Research Funds Congress has not only rejected the president’s National Institutes of Health proposal; lawmakers from both parties have joined forces to increase spending on biomedical research — and have bragged about it. [The New York Times] Editorial
| |
EVENTSNEW 11th European Breast Cancer Conference (EBCC-11) Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Director – Stanford Cancer Institute (Stanford University) Research Associate – Plasticity and Cancer (University of Cambridge) Faculty Position – Stem Cell Biology (University of Texas Southwestern Medical Center) Postdoctoral Researcher – Tumorigenesis and Stem Cell Biology (Yale University School of Medicine) Postdoctoral Fellow – Molecular Mechanisms of Cancer (Max Delbrück Center for Molecular Medicine) Assistant or Associate Professor – Cancer Immunotherapeutics (City of Hope) Assistant Professor – Cell Science (University of Manitoba) Faculty Positions – Cancer and Stem Cell Biology (Sun Yat-Sen University) Postdoctoral Fellows – Cancer Stem Cell Biology (Genome Institute of Singapore) Research Officers – Cancer Stem Cell Biology (Genome Institute of Singapore) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|